{"id":"W7098487387","doi":"","title":"DRUG NAME: Nivolumab SYNONYM(S): COMMON TRADE NAME(S): OPDIVO®","year":2015,"lang":"en","type":"article","venue":"","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Nivolumab; Monoclonal antibody; Antibody; Drug; Immunotherapy; Blocking (statistics); Receptor; Immunity","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004093112,0.0009965625,0.00110478,0.001995069,0.0006776687,0.002259598,0.001422266,0.00233785,0.2489581],"category_scores_gemma":[0.001938541,0.0002482658,0.0008123438,0.001482453,0.0004851311,0.001632443,0.0007297835,0.001412025,0.2700723],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001136193,"about_ca_system_score_gemma":0.001480415,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00142735,"about_ca_topic_score_gemma":0.001857873,"domain_scores_codex":[0.9995271,0.00005398011,0.00005566039,0.0001091383,0.0001829779,0.00007107987],"domain_scores_gemma":[0.9990828,0.00008005073,0.0001730417,0.00007487166,0.0003454063,0.0002438206],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0008203526,0.000206723,0.0005248657,0.001668012,0.00003784403,0.0005709168,0.00004863692,0.0002568904,0.01043365,0.006975893,0.5756983,0.4027579],"study_design_scores_gemma":[0.00009496512,0.0001041803,0.0003881513,0.0002877456,0.00001056802,0.0004780731,0.00001380846,0.00006510538,0.001313381,0.000420257,0.9968162,0.000007579887],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"other","genre_gemma":"other","genre_scores_codex":[0.004805862,0.04084684,0.005089324,0.005823923,0.01190934,0.001047346,0.01183003,0.002285208,0.9163621],"genre_scores_gemma":[0.04370387,0.04103889,0.007274222,0.008340525,0.004953658,0.0006631756,0.01290772,0.001837044,0.8792809],"genre_candidate":"other","genre_consensus":"other","teacher_disagreement_score":0.7510419,"threshold_uncertainty_score":0.8328478,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02475151765527463,"score_gpt":0.2857633716842759,"score_spread":0.2610118540290013,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}